Corteva sells two things that farmers must repurchase every single growing season: seeds and crop protection products. The Seed segment develops corn, soybean, and other seeds loaded with special traits, such as resistance to insects or tolerance for specific herbicides, sold under brands like Pioneer and Brevant. The Crop Protection segment sells herbicides, insecticides, and fungicides under dozens of product names including Enlist One, Delegate, and Intrepid. Farmers buy these products, use them up planting and protecting a crop, then come back and buy again the following year. Corteva reaches farmers directly through its Pioneer agency model, where independent sales representatives work face-to-face with growers, and through retail channels and third-party distributors across roughly 110 countries. The diagram below traces where the money goes.
How Corteva Makes Money
flowchart TD
A["Farmer Needs
Yield, pest control"] --> B["Seed Development
Germplasm and traits"]
A --> C["Crop Protection R&D
Herbicides, insecticides"]
B --> D["Seed Sales
$8.9B from corn, soybean"]
C --> E["Crop Protection Sales
$6.5B from herbicides, insecticides"]
D --> F["Total Revenue
$17.4B, 47% margin"]
E --> F
F --> G["Operating Cash Flow
$3.4B"]
D --> H["Direct Farmer Relationships
Pioneer agency model"]
E --> H
H --> I["Real-time Customer Insights
Future ordering, needs data"]
I --> B
I --> C
G --> J["R&D and Supply Chain
Innovation investment"]
J --> B
J --> C
Five years of financial data tell a story with two distinct chapters. From 2021 to 2022, revenue climbed from $15.7 billion to $17.5 billion, the highest point in the period. Then from 2022 through 2024, revenue drifted sideways and slightly down, settling at $16.9 billion in 2024, as Crop Protection pricing came under pressure, particularly in Latin America, and currency headwinds hit results across multiple regions. The second chapter looks more encouraging. Revenue recovered to $17.4 billion in 2025, and the story underneath the revenue line improved even more meaningfully.
Gross Margin % Over 5 Years
Gross margin has risen steadily from 40.2% in 2022 to 47.3% in 2025, meaning Corteva is keeping more of each dollar of revenue after paying direct production costs.
The gross margin improvement from 40.2 percent in 2022 to 47.3 percent in 2025 reflects a combination of cost-cutting through the Crop Protection Operations Strategy Restructuring Program, lower raw material costs, and reduced royalty payments. The restructuring program alone is expected to deliver roughly $180 million in annual savings by 2027. Free cash flow tells the same improving story. It fell sharply to $0.9 billion in 2022, likely tied to working capital demands during the revenue peak, then climbed back through $1.8 billion in 2023 and $2.1 billion in 2024, reaching $3.4 billion in 2025. That cash generation is what funded $1.5 billion returned to shareholders in 2025 through share repurchases and dividends.
$3.4B
Free cash flow in 2025, up from $0.9B in 2022
The balance sheet also strengthened. Net debt was negative $3.3 billion in 2021, meaning Corteva held more cash than debt by a wide margin. That cushion tightened through 2023 as the company put capital to work, including acquiring biological products companies Stoller and Symborg in early 2023. By 2025 the net debt position sat at negative $1.9 billion, still comfortably net cash. Corteva carries no net debt burden heading into its planned separation.
2025
milestone
Corteva Plans to Split Into Two Companies
On October 1, 2025, Corteva announced it intends to separate the Seed business and the Crop Protection business into two independent, publicly traded companies. The split is designed to be tax-free for U.S. federal income tax purposes and is targeted to complete in the second half of 2026. Each business would pursue its own growth strategy: Seed through gene editing, hybrid wheat, and out-licensing; Crop Protection through biologicals and operational efficiency.
Every number in the five-year record sits inside a company that faces real, documented threats. These are not generic disclaimers. They are specific risks with direct consequences for revenue.
Why Regulatory Approval Matters So Much Here
Before Corteva can sell a new seed trait or crop protection chemical in any country, that country's government must approve it. These approvals can take years and cost significant money. Countries can also revoke approvals already granted. Without approval, the product simply cannot be sold in that market, no matter how effective it is.
Regulatory approval is rated a high-severity risk in Corteva's own filing. New approvals are taking longer and costing more as global standards grow more complex. Environmental groups are actively filing lawsuits to block approvals for specific products including Enlist One, Corteva's flagship herbicide. If those lawsuits succeed, or if regulators revoke existing registrations, the company loses revenue from those products. The filing also flags a geopolitical supply chain risk: a material portion of Corteva's crop protection ingredients comes from China. A conflict involving China could cut off that supply. On December 6, 2025, a U.S. executive order directed the Department of Justice and the Federal Trade Commission to investigate anti-competitive practices in agriculture, including seeds. Corteva competes in exactly that market. Investigations can block acquisitions, restrict business practices, and result in financial penalties.
What Happens When a Patent Expires
A patent gives its owner the exclusive right to make and sell a product for a set period. When a patent expires, any company can legally copy the product and sell it, usually at a much lower price. The original maker typically loses a large share of that product's revenue quickly.
Patent expiration is the final high-severity risk documented in the filing. Corteva's competitive position depends heavily on proprietary seed traits and crop protection chemistries. When key patents expire, generic manufacturers can copy and undercut those products. The Enlist E3 soybean trait is now the leading herbicide tolerance technology for soybeans in the United States, used across substantially all of Corteva's branded soybean portfolio. How long that lead holds against future patent expiry and competing traits will matter enormously to the Seed segment's revenue.
$1,474M
Research and development spending in 2025, equal to 8% of net sales
Corteva spends $1,474 million per year on research and development, equal to 8 percent of net sales, to keep new products ahead of expiring older ones. That spending has grown every year in the data provided. The question is whether the pipeline it funds can consistently generate products that replace revenue lost to patent expiry and generic competition. The planned split into two separate companies adds another layer of uncertainty, because each standalone business will have to carry its own cost structure and capital allocation without the other to lean on.
Corteva generates about 60 percent of its sales in the first half of the calendar year, aligned with planting season in the northern hemisphere. This means quarterly results swing widely by season and are not a reliable guide to full-year performance.
$0.9B
Free Cash Flow 2022
$3.4B
Free Cash Flow 2025
Cash generation nearly quadrupled over three years, driven by cost restructuring, lower raw material costs, and margin expansion, even as revenue stayed roughly flat.
The Bet
Corteva's new products must continuously outpace the revenue erosion from expiring patents on older ones. The entire model depends on a pipeline running at $1,474 million per year in research spending generating differentiated seeds and crop chemicals that farmers are willing to pay premium prices for, year after year, across a globally fragmented and increasingly competitive regulatory environment. If generic competitors close the performance gap faster than the pipeline delivers new protected products, the pricing power that drove gross margin from 40.2 percent to 47.3 percent starts to reverse. The planned separation into two companies makes this test harder, because each business will have to sustain its own pipeline investment without the other's cash flows as a buffer.
Open question
Corteva is splitting into two separate companies by late 2026. The Seed business and the Crop Protection business currently share costs, cash flows, and risk. Once separated, each must stand on its own. The Crop Protection side faces active litigation against key products, ingredient supply concentrated in China, and ongoing generic price pressure. The Seed side holds the leading soybean trait in the United States but faces antitrust scrutiny and patent clocks that keep running. Can both businesses independently sustain the research spending needed to stay ahead of patent expiry and generic competition once they no longer share a balance sheet?
Compiled · 10-K · FY2025
Regulatory Approval Risk
Corteva must get government approval before selling new seeds with special traits and crop protection products. These approvals take a long time, cost a lot of money, and have unpredictable rules that change by country. If Corteva cannot get or keep these approvals, it cannot sell many of its products and will lose significant sales.
Litigation and Public Opposition
Environmental and public interest groups are filing lawsuits to block approvals for Corteva's pesticide products like Enlist One, and some groups claim crop protection products harm health and the environment. These lawsuits and negative publicity could prevent Corteva from selling products, damage its reputation, and result in large legal costs and settlements.
Supply Chain Geopolitical Risk
A material portion of Corteva's crop protection ingredients come from China. If conflict erupts between China and Taiwan or the United States, Corteva could lose access to these supplies, face higher costs, and be unable to deliver products to customers, materially harming its business.
Antitrust Investigation
On December 6, 2025, President Trump issued an executive order directing the Department of Justice and Federal Trade Commission to investigate anti-competitive conduct in agriculture, including seeds. These investigations and potential enforcement actions could restrict Corteva's business practices, block mergers and acquisitions, and result in fines or penalties.
Product Patent Expiration
When Corteva's patents expire on key products, generic manufacturers can legally copy and sell those products at lower prices. Corteva could lose a major portion of revenue from that product, which would materially hurt its financial results.
10-K Item 1A · Risk Factors
